Rhumbline Advisers lowered its position in Myriad Genetics, Inc. (NASDAQ:MYGN) by 1.0% during the first quarter, according to its most recent filing with the SEC. The firm owned 204,889 shares of the company’s stock after selling 2,172 shares during the period. Rhumbline Advisers’ holdings in Myriad Genetics were worth $6,802,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Teachers Advisors LLC raised its position in shares of Myriad Genetics by 2.0% in the 3rd quarter. Teachers Advisors LLC now owns 126,948 shares of the company’s stock worth $5,840,000 after buying an additional 2,490 shares during the period. Vanguard Group Inc increased its holdings in Myriad Genetics by 4.4% in the 3rd quarter. Vanguard Group Inc now owns 8,656,933 shares of the company’s stock valued at $398,219,000 after purchasing an additional 365,697 shares in the last quarter. Bank of Montreal Can increased its holdings in Myriad Genetics by 2.0% in the 4th quarter. Bank of Montreal Can now owns 95,569 shares of the company’s stock valued at $2,778,000 after purchasing an additional 1,847 shares in the last quarter. Ingalls & Snyder LLC increased its holdings in Myriad Genetics by 1.2% in the 4th quarter. Ingalls & Snyder LLC now owns 49,526 shares of the company’s stock valued at $1,440,000 after purchasing an additional 605 shares in the last quarter. Finally, Fisher Asset Management LLC increased its holdings in Myriad Genetics by 3.2% in the 4th quarter. Fisher Asset Management LLC now owns 132,412 shares of the company’s stock valued at $3,849,000 after purchasing an additional 4,141 shares in the last quarter. Hedge funds and other institutional investors own 99.22% of the company’s stock.
Shares of Myriad Genetics stock opened at $24.14 on Friday. The company has a debt-to-equity ratio of 0.24, a current ratio of 3.15 and a quick ratio of 2.86. The stock has a market cap of $1.89 billion, a PE ratio of 20.12, a price-to-earnings-growth ratio of 1.54 and a beta of 0.55. Myriad Genetics, Inc. has a 1-year low of $23.93 and a 1-year high of $50.44.
MYGN has been the subject of several recent research reports. Needham & Company LLC reiterated a “strong-buy” rating and issued a $41.00 price target (up from $37.00) on shares of Myriad Genetics in a report on Tuesday, March 12th. BidaskClub upgraded Myriad Genetics from a “hold” rating to a “buy” rating in a report on Wednesday, March 27th. Finally, Zacks Investment Research upgraded Myriad Genetics from a “hold” rating to a “buy” rating and set a $31.00 price target for the company in a report on Wednesday, January 30th. Three investment analysts have rated the stock with a sell rating, four have issued a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $39.19.
In other news, insider Ralph L. Mcdade sold 1,975 shares of the firm’s stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $31.00, for a total transaction of $61,225.00. Following the completion of the sale, the insider now directly owns 122,604 shares in the company, valued at $3,800,724. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 5.80% of the stock is owned by company insiders.
WARNING: “Myriad Genetics, Inc. (MYGN) Stake Lessened by Rhumbline Advisers” was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international copyright law. The legal version of this report can be viewed at https://www.tickerreport.com/banking-finance/4351153/myriad-genetics-inc-mygn-stake-lessened-by-rhumbline-advisers.html.
Myriad Genetics Profile
Myriad Genetics, Inc, a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.
Want to see what other hedge funds are holding MYGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Myriad Genetics, Inc. (NASDAQ:MYGN).
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.